This funding opportunity supports independent initiatives including research, quality improvement, or education aimed at improving patient outcomes in idiopathic inflammatory myopathies. Projects must align with Pfizer's medical and scientific strategies and focus on real-world evidence through a German disease registry.
Applicants must be based in Germany. Eligibility is limited to initiatives aligned with Pfizer's medical and scientific strategies.
